Australian (ASX) Stock Market Forum

GSS - Genetic Signatures

This month's post for the yearly Comp @mullokintyre

Sideways or even down, a low for the CY
.
Q HIGHLIGHTS
• Quarterly sales of $4.4 million, in line with the prior corresponding period reflecting higher testing rates typically experienced during the Australian winter respiratory season;
• Organisational changes implemented during the quarter, including changes to US leadership and focused reorganisation of US team to better align with current strategy and needs;
• Ramp-up of US sales have been impacted by prospective customers’ internal processes, competing priorities, preference for enhanced workflow and uncertainty in the US healthcare environment. Subsequent to quarter end an additional US contract was signed with an integrated health care organisation;
• Development of automated, high-throughput solution through customisation of commercially available instruments commenced with establishment of strategic three-way partnership;
• Strong engagement with molecular experts globally, with relevant key opinion leaders presenting at leading European conference to showcase the benefits of the Company’s molecular diagnostic solutions; and
• Strong balance sheet with $30.9 million cash balance at 30 June 2025

, .... coming off lows, but a dud. Homework eaten by dog.
Screenshot_20250722_090101_CommSec~2.jpg
 
This month's post for the yearly Comp @mullokintyre

$0.29

FY HIGHLIGHTS
• Revenue grew 63% to $15.9m, delivering strong year-on-year growth
• Underlying loss reduced 28% to $12.7m, reflecting disciplined execution
• Statutory loss of $20.1m includes $7.0m impairment
• $30.9m cash, zero debt – strong foundation for growth
• Key partnerships with Tecan Group and Repado to launch next-generation automated solution
• First US commercial contract secured – unlocking a major market
• Strengthened business foundations to accelerate sustainable growth

Screenshot_20250825_092316_Drive~2.jpg
 
Top